OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint
OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells. The company showed the mAbs increased macrophage and dendritic cell activity against tumor cells. In mice modeling colon cancer, CLEC1A knockout led to more CD8⁺ T cell proliferation and, when combined with chemotherapy, reduced tumor growth. OSE reported the data in two abstracts ahead of the virtual American Association for Cancer Research meeting.

NCI’s serological testing program
...